Should I buy Lifestance Health (LFST) stock or is it too late?

Lifestance Health · Health Care · price $12

See the full Lifestance Health (LFST) profile

⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

Firm-by-firm track record on Lifestance Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Morgan Stanley	40 %	-14.6 %	5	$10 -19%

In short — Should you invest in Lifestance Health? Is it too late, still worth it? Analysts are fairly positive (67% buy, median target $13, i.e. +6%), and the most reliable on LFST targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

67% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
The most reliable firm on LFST, Barclays (100% hit rate, 3 scored calls), targets $13 (call made on July 14, 2026, maturing on July 14, 2027) (+6%) in its most recent call, and $8 (call made on December 9, 2025, maturing on December 9, 2026) (-35%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 6 ratings, 2 are neutral.
Limited upside: the median target is only +6% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on LFST

Median target $13 (+6%) · 6 ratings · Buy consensus

Strong Buy00%

Buy467%

Hold233%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Lifestance Health now?

We won't decide for you. The facts: 67% of analysts rate it a buy, median target $13 (+6%), and Barclays (most reliable on LFST, 100%) targets $13. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Lifestance Health?

Not according to analysts: the median target ($13) is still +6% above the current price ($12) (most reliable on LFST: Barclays, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Lifestance Health still worth investing in?

It depends on the gap between the price ($12) and its estimated value: analysts target $13 on median (+6%), with 67% buys (most reliable on LFST: Barclays, 100%). Cross-check with their real reliability on LFST and the cautions above. Information, not advice.

What's the main risk in buying LFST?

The consensus is not unanimous: of 6 ratings, 2 are neutral.

→ Go deeper: the full Lifestance Health profile (consensus, analyst reliability, price target, performance).